Kura Oncology (NASDAQ:KURA) Stock Price Breaks Above 200-Day Moving Average – Here’s What Happened

Posted by Brenda Bartman on Oct 29th, 2026

Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $9.79 and traded as high as $9.90. Kura Oncology shares last traded at $9.90, with a volume of 1,709,700 shares trading hands.

Analysts Set New Price Targets

Several equities research analysts have commented on KURA shares. Citizens Jmp reissued a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a report on Monday, August 24th. Deutsche Bank Aktiengesellschaft set a $24.00 target price on Kura Oncology in a research note on Wednesday, October 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, October 15th. Raymond James Financial set a $24.00 price target on Kura Oncology in a research report on Monday, August 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, October 14th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.35.

Read Our Latest Report on KURA

Kura Oncology Trading Down 1.5%

The firm has a market cap of $939.42 million, a P/E ratio of -3.13 and a beta of 0.47. The stock has a fifty day simple moving average of $11.22 and a 200 day simple moving average of $9.80. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73.

Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. The business had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. On average, research analysts expect that Kura Oncology, Inc. will post -3.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Teresa Bair sold 8,442 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $10.50, for a total value of $88,641.00. Following the transaction, the insider owned 187,002 shares of the company’s stock, valued at approximately $1,963,521. This trade represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Kathleen Ford sold 3,668 shares of the firm’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total transaction of $39,431.00. Following the completion of the transaction, the chief operating officer directly owned 142,986 shares in the company, valued at approximately $1,537,099.50. The trade was a 2.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 153,881 shares of company stock valued at $1,708,183 in the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Kura Oncology during the second quarter valued at about $115,286,000. Dimensional Fund Advisors LP lifted its position in shares of Kura Oncology by 32.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after buying an additional 348,127 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Kura Oncology by 46.1% during the 1st quarter. Bank of America Corp DE now owns 1,230,131 shares of the company’s stock valued at $10,001,000 after buying an additional 388,003 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Kura Oncology during the 2nd quarter valued at approximately $10,927,000. Finally, Pale Fire Capital SE grew its stake in shares of Kura Oncology by 89.6% during the 1st quarter. Pale Fire Capital SE now owns 857,474 shares of the company’s stock valued at $6,971,000 after acquiring an additional 405,229 shares during the period.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc (NASDAQ: KURA) is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target genetic and molecular drivers of malignancies, with the goal of developing therapies for patients with limited treatment options.

Kura’s lead product candidate has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia (AML), including AML associated with NPM1 mutations and KMT2A rearrangements.